BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsFinancing

Single healthcare-focused institutional investor

$5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants

Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV,...

Related news

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ELTXElicio Therapeutics, Inc.2026-07-06 20:05 EST

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

ELTXElicio Therapeutics, Inc.2026-07-02 04:25 EST

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

BCTXBriaCell2026-06-02 20:05 EST

BriaCell Therapeutics Announces Closing of Offering

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

BCTXBriaCell2026-05-31 23:59 EST

BriaCell Therapeutics Announces Pricing of Offering

MDNAMedicenna Therapeutics Corp.2026-05-28 13:10 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States